D.E. Shaw & Co
FSTX

D.E. Shaw & Co’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

D.E. Shaw & Co’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,865
Closed -$56K – 5967
2022
Q1 		$56K Buy
+15,865
New +$58.6K ﹤0.01% 5121

Other funds holding FSTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's FSTX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2022, closing a stake of 15,865 shares — an estimated $56K sold.

D.E. Shaw & Co first reported a position in FSTX in Q1 2022 and held it in 1 quarter. The position peaked at $56K in Q1 2022. 53 funds tracked by Wall St. Rank hold FSTX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,865 F-star Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $56K.
  • D.E. Shaw & Co first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • D.E. Shaw & Co's F-star Therapeutics, Inc. Common Stock position peaked at $56K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.